文献速递胸部肿瘤

致癌性EGFR-SHC1融合通过双重激活机制导致肺癌对EGFR-TKI不敏感

The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.
PubMed 文献 · Cancer Discov · 2026-01-01

在非小细胞肺癌中发现的EGFR-SHC1融合亚型在临床前和临床环境中对EGFR-TKI单药治疗表现出内在耐药。该融合蛋白同时激活EGFR激酶结构域和SRC介导的SHC1磷酸化,驱动ERK/AKT通路激活和肿瘤发生。阿法替尼联合达沙替尼在TKI难治性患者中诱导显著肿瘤消退,提示双靶向抑制策略可克服耐药。

要点

  • EGFR-SHC1融合是EGFR融合中對EGFR-TKI单药内在耐药的亚型。
  • 耐药机制为EGFR激酶结构域与SHC1磷酸化双重激活。
  • 阿法替尼联合达沙替尼在TKI难治患者中诱导显著肿瘤消退。

核心结论

  • EGFR-SHC1融合通过激酶依赖和非激酶依赖的双重机制驱动肿瘤发生并对EGFR-TKI单药耐药。

研究设计与样本

  • 临床前与临床环境下的融合亚型鉴定与机制研究。

主要发现

  • EGFR-SHC1融合蛋白由N端EGFR和C端SHC1组成,同时激活EGFR激酶结构域和SRC介导的SHC1磷酸化。
  • SHC1磷酸化建立不依赖激酶旁路机制,驱动ERK/AKT通路激活和肿瘤发生。
  • 阿法替尼联合达沙替尼在TKI难治性EGFR-SHC1 NSCLC患者中诱导显著肿瘤消退。

临床怎么用

  • 对EGFR融合NSCLC患者应识别EGFR-SHC1亚型,避免单药EGFR-TKI治疗。
  • EGFR-SHC1融合患者可考虑EGFR-TKI联合SRC-TKI的双靶向抑制策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Although epidermal growth factor receptor (EGFR) fusions in non-small cell lung cancer (NSCLC) typically show sensitivity to tyrosine kinase inhibitors (TKI), we identified an EGFR-SHC1 fusion subtype that exhibits intrinsic resistance to EGFR-TKI monotherapy through a dual-activation mechanism in the preclinical and clinical settings. EGFR-SHC1 fusion protein comprises of N-terminal EGFR and C-terminal SHC1. We demonstrated that EGFR-SHC1 simultaneously activates the EGFR kinase domain (KD) and SRC-mediated phosphorylation of the SHC1 fusion partner, thereby driving ERK/AKT pathway activation and tumorigenesis independent of KD inhibition. Structural modeling coupled with domain-specific mutagenesis revealed that SHC1 phosphorylation establishes a kinase-independent bypass mechanism. Notably, dual-targeted inhibition using afatinib (EGFR-TKI) in combination with dasatinib (SRC-TKI) induced marked tumor regression in a TKI-refractory patient with NSCLC with EGFR-SHC1. This study illustrates a cooperative oncogenesis between kinases and scaffold proteins in fusions, providing a clinically actionable strategy for overcoming TKI resistance in patients with these oncogenic fusions. SIGNIFICANCE: This study identifies a previously unrecognized mode of oncogenic signaling in receptor tyrosine kinase (RTK) fusions, in which a non-kinase fusion partner actively drives tumorigenesis through kinase-independent mechanisms. By challenging the classical kinase-centric model of RTK fusions, it provides a framework for understanding intrinsic resistance to TKIs and for developing rational combination therapies. See related commentary by Le and Wolf, p. 1480.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Zheng J, Zhao S, Zhan J, et al. The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer. Cancer Discov. 2026. PMID: 41874451. doi:10.1158/2159-8290.CD-25-1936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。